Russell Investments Group Ltd. Boosts Stock Position in Krystal Biotech, Inc. $KRYS

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Krystal Biotech by 8,390.1% after purchasing 37,336 shares, raising its total ownership to 37,781 shares valued at approximately $6.81 million.
• Several institutional investors have also increased their holdings in Krystal Biotech, contributing to a total institutional ownership of 86.29% of the company's stock.
• Krystal Biotech recently reported earnings of $1.29 per share, exceeding expectations, with a net margin of 40.85% and projected full-year earnings of $6.14 per share.

Russell Investments Group Ltd. boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8,390.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,781 shares of the company's stock after buying an additional 37,336 shares during the period. Russell Investments Group Ltd. owned 0.13% of Krystal Biotech worth $6,812,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its stake in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Krystal Biotech in the 4th quarter worth about $95,000. GAMMA Investing LLC boosted its stake in Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Krystal Biotech in the 1st quarter worth about $223,000. Finally, Avanza Fonder AB raised its holdings in shares of Krystal Biotech by 66.0% in the 1st quarter. Avanza Fonder AB now owns 1,260 shares of the company's stock worth $228,000 after purchasing an additional 501 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded up $0.11 during mid-day trading on Tuesday, hitting $146.88. 278,094 shares of the company traded hands, compared to its average volume of 417,806. The firm has a market cap of $4.25 billion, a P/E ratio of 29.85 and a beta of 0.70. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The firm's 50 day simple moving average is $144.84 and its 200 day simple moving average is $154.39.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The company had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on KRYS. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday. Chardan Capital cut their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday. Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Citigroup restated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $210.38.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).